&NA;TP 9201, a synthetic RGD-containing cyclic peptide, is a glycoprotein IIb/IIIa receptor antagonist which has undergone phase I trials in the US as an antithrombotic agent for the treatment of thromboses associated with acute unstable angina pectoris, restenosis, reocclusion, ischaemic stroke, and reperfusion injury resulting from vascular grafts, reconstructive surgery and organ transplantation. Telios Pharmaceuticals (Integra LifeSciences) and Genentech were originally collaborating on the development of TP 9201, but in October 1992 Telios acquired the worldwide rights to TP 9201. TP 9201 is available for licensing worldwide.